The goal of this educational initiative is to provide hematologists, other physicians, and allied healthcare providers (including nurse practitioners and physician assistants), who care for patients with hemophilia A, with the knowledge and skills necessary to make the most appropriate treatment choices for their patients, based on patient preferences and lifestyle and interpatient variability in pharmacokinetics, and to predict, prevent, and manage inhibitor formation.

This educational initiative is intended to meet the needs of hematologists, other physicians, as well as allied healthcare practitioners (nurse practitioners and physician assistants) who care for patients with hemophilia A. There are no prerequisites.

After participating in this activity, the participant should be able to:
  • REVIEW advances in factor-based prophylaxis, including extended half-life factors, for managing hemophilia.
  • DESCRIBE the impact of interpatient variability in clotting factor PK profiles on subsequent bleeding risk and related limitations of weight-based dosing.
  • EVALUATE recent clinical and technological advances to optimize clotting factor dosing on an individual patient basis.
  • ASSESS current and emerging strategies to predict and manage inhibitor development.
  • PROPOSE patient-specific prophylactic treatment paradigms for hemophilia A considering the latest evidencebased knowledge.
joint-accred-logo_smIn support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Rush University Medical Center designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.

After reviewing this activity, participants may receive a certificate by receiving a score of 80% or higher on the CME test and completing an evaluation. A certificate of participation will be available online immediately following successful completion of the activity.

The estimated time to complete this educational activity: 2 hours.

Release date: November 21, 2019. Expiration date: November 21, 2020.

Media:This CME activity is available as a printed piece and a web-based supplement.

Please complete a brief preassessment before continuing with the supplement. After reading this supplement, participants may receive a certificate by receiving a score of 80% or higher on the CME test and completing an evaluation. Certificates can be printed immediately online.

There is no fee for participating in this activity.

Mindy L. Simpson, MD
Assistant Professor of Pediatrics
Pediatric Hematology/Oncology
Director, Rush Hemophilia and Thrombophilia Center
Rush University Medical Center
Chicago, Illinois

Lisa N. Boggio, MD
Assistant Professor of Pediatrics
Rush University Medical Center
Rush Hemophilia and Thrombophilia Center
Chicago, Illinois

It is the policy of the Rush University Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias, and beyond the control of persons or organizations with an economic interest in influencing the content of CE. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months.

Unapproved Uses of Drugs/Devices: In accordance with requirements of the US Food and Drug Administration (FDA), the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information. The following relationships have been reported for this activity:

Dr Boggio reports serving as a consultant for Baxalta Inc, Bayer, Bioverativ Inc, CSL Behring, Novo Nordisk,Takeda Pharmaceutical Company Ltd, and Octapharma.

Dr Simpson reports serving on speakers' bureaus for Bayer and Novo Nordisk; and serving as a consultant for Bayer, CSL Behring, Genentech Inc, HEMA Biologics, Novo Nordisk, Octapharma, and Takeda Pharmaceutical Company Ltd.



A Plethora of Choices: A Look at the Breadth of Standard and Extended Half-Life Factor VIII Products

The Challenge of Prophylaxis Dosing: Advances in Individualized Dosing to Improve Outcomes

Addressing Inhibitor Development in Hemophilia A: Prediction, Prevention, and Treatment

Clinical Cases in Hemophilia A: Applying Advances to Practice

Changing Direction Towards Individualized Care in Hemophilia A

Post Assessment

Submit a case to review at meeting:

procced to pretest

MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC. Contact Us